Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

NCT05095207 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

NCT03703466 ·Status: COMPLETED ·Phase: PHASE2

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

NCT02747004 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

NCT00645177 ·Status: COMPLETED ·Phase: PHASE2

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

NCT03988114 ·Status: WITHDRAWN ·Phase: PHASE4

First Line Therapy for Patients With Metastatic Breast Cancer

NCT00456846 ·Status: TERMINATED ·Phase: PHASE2

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

NCT03155997 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas

NCT06389123 ·Status: RECRUITING ·Phase: PHASE1

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

NCT06365788 ·Status: RECRUITING ·Phase: PHASE2

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

NCT01069796 ·Status: TERMINATED ·Phase: PHASE2

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT02441946 ·Status: COMPLETED ·Phase: PHASE2

A Study of LY2523355 in Participants With Breast Cancer

NCT01416389 ·Status: COMPLETED ·Phase: PHASE2

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00654836 ·Status: COMPLETED ·Phase: PHASE2

Lapatinib and Bevacizumab for Metastatic Breast Cancer

NCT00444535 ·Status: COMPLETED ·Phase: PHASE2

Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

NCT04923542 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Exploratory Study of Breast Cancer With ABY025

NCT01216033 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model

NCT00468585 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer

NCT00005817 ·Status: COMPLETED ·Phase: PHASE2

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

NCT00472693 ·Status: COMPLETED ·Phase: PHASE2

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

NCT00093145 ·Status: COMPLETED ·Phase: PHASE2

Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

NCT03870919 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer

NCT00083031 ·Status: COMPLETED ·Phase: PHASE2

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

NCT00520975 ·Status: TERMINATED ·Phase: PHASE3

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

NCT02688088 ·Status: COMPLETED ·Phase: PHASE1

Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer

NCT00868634 ·Status: COMPLETED ·Phase: PHASE3